Diltiazem Market Examined in New Research Report
Added: (Thu Sep 22 2022)
Pressbox (Press Release) -
According to our latest study on “Diltiazem Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product type and application,” the market is projected to reach US$ 832.51 million by 2028 from US$ 369.95 million in 2021; it is expected to grow at a CAGR of 12.3% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.
Market leaders operating in the market have undertaken various organic growth strategies in the Diltiazem market. The Diltiazem market majorly consists of the players Bausch Health, Teva Pharmaceutical Industries Ltd, Mylan N.V, Athenex, Pfizer, Inc, Glenmark, Sandoz (Novartis Ag), Sun Pharmaceutical Company Ltd, Hikma Pharmaceuticals, Zydus Pharmaceuticals among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Based on product type, the diltiazem market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market, whereas the capsules segment is expected to witness the fastest CAGR during the forecast period. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
Bausch Health; Teva Pharmaceutical Industries Ltd; Mylan N.V; Athenex; Pfizer, Inc; Glenmark; Sandoz (Novartis Ag); Sun Pharmaceutical Company Ltd; Hikma Pharmaceuticals; and Zydus Pharmaceuticals are among the companies operating in the diltiazem market.